Webinar Date/Time: Wednesday, June 12th, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Do you know what challenges are encountered by sites when operationalizing study protocols? In this webinar, learn how specific protocol design elements impact sites’ perception of burden and how this information can be used to improve site experience.
Register Free: https://www.pharmexec.com/pe/data-driven
Event Overview:
Sites can encounter a wide range of challenges when operationalizing study protocols, including the need to manage frequent and lengthy patients visits, coordinate complicated procedure schedules and utilize multiple disparate technology systems. Applied analytics enable data-driven protocol design that can help sponsors mitigate these trial challenges.
Data collected from sites can help uncover specific protocol elements that drive sites’ perception of burden. These findings can be used to optimize protocol design to decrease burden and improve site experience, potentially leading to positive outcomes such as facilitating the collection of cleaner data and improving protocol compliance.
Three key take-aways
This concludes our webinars in the 3-part Applying data for Improved Protocol Design series. You can access Webinar #1 here and Webinar #2 here.
Speaker:
Betsy Wagner
Design Analytics Director
IQVIA
Betsy Wagner has a strong background in clinical site operations, specialized in oncology trials. Her site experience includes both academic centers and community-based sites, while working at CROs and recruitment technology service providers. Betsy has built and expanded programs, conducting both NCI and industry sponsored trials, providing a strong foundation in regulatory, feasibility and enrollment operations as well as strategic program growth. While holding these roles, Betsy gained a reputation for success in pressure testing protocols, including consulting with several national groups on smarter protocol design. She recently joined IQVIA, where she leverages her experience to improve clinical trial design for all stakeholders—sponsors, sites, and patients.
Register Free: https://www.pharmexec.com/pe/data-driven
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.